CA 22873/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Save citations to file

Email citations

Your saved search

Your RSS Feed

Year	Number of Results
1987	1
1988	2
2025	0

Page 1

Expansion of activated T-lymphocytes in patients treated with recombinant interleukin 2.

Kolitz JE, Welte K, Wong GY, Holloway K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Polivka A, Gabrilove JL, et al. Kolitz JE, et al. J Biol Response Mod. 1987 Aug;6(4):412-29. J Biol Response Mod. 1987. PMID: 3498011

Phase I trial of recombinant interleukin-2 and cyclophosphamide: augmentation of cellular immunity and T-cell mitogenic response with long-term administration of rIL-2.

Kolitz JE, Wong GY, Welte K, Merluzzi VJ, Engert A, Bialas T, Polivka A, Bradley EC, Konrad M, Gnecco C, et al. Kolitz JE, et al. J Biol Response Mod. 1988 Oct;7(5):457-72. J Biol Response Mod. 1988. PMID: 3263471

A phase I trial of intraperitoneal recombinant interleukin 2 in patients with ovarian carcinoma.

Chapman PB, Kolitz JE, Hakes TB, Gabrilove JL, Welte K, Merluzzi VJ, Engert A, Bradley EC, Konrad M, Mertelsmann R. Chapman PB, et al. Invest New Drugs. 1988 Sep;6(3):179-88. doi: 10.1007/BF00175395. Invest New Drugs. 1988. PMID: 3263958

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year